Resultados da pesquisa - Kent A. Robertson
- A mostrar 1 - 10 resultados de 10
-
1
-
2
-
3
-
4
Semiquantitative Epstein-Barr Virus (EBV) Polymerase Chain Reaction for the Determination of Patients at Risk for EBV-Induced Lymphoproliferative Disease After Stem Cell Transplant... Por Kenneth G. Lucas, Robert L. Burton, Sarah E. Zimmerman, Jinghong Wang, Kenneth Cornetta, Kent A. Robertson, Chao H. Lee, David J. Emanuel
Publicado em 1998Artigo -
5
The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression Por Ying Guo, Robert H. Costa, H. E. Ramsey, Trevor Starnes, Gail H. Vance, Kent A. Robertson, Mark R. Kelley, Rolland Reinbold, Hans R. Schöler, Robert Hromas
Publicado em 2002Artigo -
6
Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation Por Ayman Akil, Qing Zhang, Christen L. Mumaw, Nisha Raiker, Jeffrey Yu, Nieves Vélez de Mendizábal, Laura S. Haneline, Kent A. Robertson, Jodi Skiles, Maribel Díaz‐Ricart, Enric Carreras, Jamie L. Renbarger, Samir Hanash, Robert R. Bies, Sophie Paczesny
Publicado em 2015Artigo -
7
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow Por Feng‐Chun Yang, David A. Ingram, Shi Chen, Yuan Zhu, Jin Yuan, Xiaohong Li, Xianlin Yang, Scott M. Knowles, Whitney Horn, Yan Li, Shaobo Zhang, Yanzhu Yang, Saeed T. Vakili, Menggang Yu, Dennis K. Burns, Kent A. Robertson, Gary D. Hutchins, Luis F. Parada, D. Wade Clapp
Publicado em 2008Artigo -
8
Recommendations for imaging tumor response in neurofibromatosis clinical trials Por Eva Dombi, Simone Ardern‐Holmes, Dusica Babovic‐Vuksanovic, Fred G. Barker, Steve Connor, D. Gareth Evans, Michael J. Fisher, Stéphane Goutagny, Gordon J. Harris, Diego Jaramillo, Matthias A. Karajannis, Bruce R. Korf, Victor Mautner, Scott R. Plotkin, Tina Young Poussaint, Kent A. Robertson, Chie‐Schin Shih, Brigitte C. Widemann
Publicado em 2013Artigo -
9
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial Por Kent A. Robertson, Grzegorz Nalepa, Feng‐Chun Yang, Daniel C. Bowers, Chang Yueh Ho, Gary D. Hutchins, James M. Croop, Terry A. Vik, Scott C. Denne, Luis F. Parada, Cynthia M. Hingtgen, Laurence E. Walsh, Menggang Yu, Kamnesh R. Pradhan, Mary Edwards‐Brown, Mervyn D. Cohen, James Fletcher, Jeffrey B. Travers, Karl Staser, Melissa W. Lee, Marcie R. Sherman, Cynthia J. Davis, Lucy Miller, David A. Ingram, D. Wade Clapp
Publicado em 2012Artigo -
10
Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial Por Michael J. Fisher, Chie‐Schin Shih, Steven D. Rhodes, Amy E. Armstrong, Pamela L. Wolters, Eva Dombi, Chi Zhang, Steven P. Angus, Gary L. Johnson, Roger J. Packer, Jeffrey C. Allen, Nicole J. Ullrich, Stewart Goldman, David H. Gutmann, Scott R. Plotkin, Tena Rosser, Kent A. Robertson, Brigitte C. Widemann, Abbi E. Smith, Waylan Bessler, Yongzheng He, Su Jeong Park, Julie A. Mund, Jiang Li, Khadijeh Bijangi‐Vishehsaraei, Coretta Thomas Robinson, Gary Cutter, Bruce R. Korf, Chie‐Schin Shih, Amy E. Armstrong, Jaishri O. Blakeley, D. Wade Clapp
Publicado em 2021Artigo
Ferramentas de pesquisa:
Assuntos relacionados
Biology
Gene
Medicine
Biochemistry
Cell biology
Genetics
Immunology
Internal medicine
Neurofibromatosis
Cancer research
Gastroenterology
Molecular biology
Pathology
Receptor
Retinoic acid
Retinoic acid receptor
Retinoic acid-inducible orphan G protein-coupled receptor
Transcription factor
Adverse effect
Cancer
Cell culture
Cellular differentiation
Chemistry
Embryonic stem cell
Haematopoiesis
Myeloid leukemia
Neurofibroma
Nuclear receptor
Oncology
Organic chemistry